Should C4d Be Used as a Marker in Pancreas Transplant Biopsies?

Ron Shapiro, MD


August 30, 2010

This feature requires the newest version of Flash. You can download it here.

Hi, my name is Ron Shapiro. I'm a transplant surgeon at the University of Pittsburgh, and today I want to talk to you about rejection in pancreas transplant recipients.

We all know that C4d staining has been important in the diagnosis of antibody-mediated rejection in kidney transplant patients. But there have been fewer data with regard to nonrenal transplant recipients. The analysis from both Leiden [The Netherlands] and the University of Maryland suggest that, not surprisingly, both donor-specific and C4d staining were important negative prognostic factors in patients with pancreas allograft projection after pancreas transplantation.[1]

The importance of this report, I believe, lies in the generalizability of C4d as a bad actor in patients undergoing all sorts of solid organ transplant procedures. It is interesting to see that it holds true in the pancreas recipients as well as in the kidney recipients. Thank you.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: